title: [Botulinum neurotoxin type A in neurogenic detrusor overactivity: consensus paper of the Working Group Neuro-Urology of the DMGP].
abstract: The use of botulinum neurotoxin (BoNT-A) for suppression of neurogenic detrusor overactivity was first reported in 2000. Since that time, this method has gained widespread use. A number of recommendations and consensus statements have already been published. The current practice-oriented consensus paper takes into account recent developments and the over 10-year experience of most members of the Working Group Neuro-Urology of the German-speaking Medical Society for Paraplegia (DMGP) with a focus on the use of BoNT-A in paraplegic patients and in patients with multiple sclerosis.
authors.affiliation: Abteilung Neuro-Urologie, Querschnittgelähmtenzentrum, Berufsgenossenschaftliches Unfallkrankenhaus Hamburg, Bergedorfer Straße 10, 21033, Hamburg, Deutschland, rboethig@gmx.de.
authors.forename: R
authors.initials: R
authors.lastname: Böthig
authors.forename: A
authors.initials: A
authors.lastname: Kaufmann
authors.forename: J
authors.initials: J
authors.lastname: Bremer
authors.forename: J
authors.initials: J
authors.lastname: Pannek
authors.forename: B
authors.initials: B
authors.lastname: Domurath
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000553:Ambulatory Care; D019274:Botulinum Toxins, Type A / Q000009:adverse effects / Q000627:therapeutic use*; D017277:Drug Approval; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications*; D009498:Neurotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D056687:Off-Label Use; D010264:Paraplegia / Q000150:complications*; D010343:Patient Admission; D011247:Pregnancy; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D009498:Neurotoxins; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA